Quizartinib Tablets Market
The market for Quizartinib Tablets was estimated at $612 million in 2024; it is anticipated to increase to $1.04 billion by 2030, with projections indicating growth to around $1.63 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Quizartinib Tablets Market Outlook
Revenue, 2024
$612M
Forecast, 2034
$1.49B
CAGR, 2025 - 2034
9.3%
The Quizartinib Tablets industry revenue is expected to be around $669.0 million in 2025 and expected to showcase growth with 9.3% CAGR between 2025 and 2034. The market continues to gain clinical and commercial importance due to the growing focus on targeted therapies for acute myeloid leukemia and the increasing adoption of precision oncology approaches in hematologic cancer treatment. Rising prevalence of FLT3 mutated acute myeloid leukemia, expanding molecular diagnostic testing, and improving awareness regarding personalized cancer therapies are significantly supporting market demand. Pharmaceutical companies and oncology research institutions are actively investing in next generation kinase inhibitors and combination therapy strategies to improve patient outcomes and reduce relapse rates. In addition, favorable regulatory approvals, expanding reimbursement frameworks, and increasing integration of biomarker driven treatment protocols in oncology care are strengthening the ongoing relevance of quizartinib tablets within modern leukemia treatment pathways globally.
Quizartinib tablets are targeted oral anticancer therapies primarily used for the treatment of FLT3 internal tandem duplication positive acute myeloid leukemia, particularly in adult patients with newly diagnosed or relapsed disease. Quizartinib functions as a selective FLT3 kinase inhibitor that blocks abnormal leukemia cell proliferation by targeting specific genetic mutations associated with aggressive disease progression. These tablets are commonly administered in combination with chemotherapy or as part of maintenance therapy protocols in hematologic oncology treatment programs. Key features include targeted molecular activity, oral administration convenience, and improved disease management for genetically defined patient populations. Recent market trends include increasing use of companion diagnostics, expansion of personalized oncology treatment frameworks, and growing clinical research evaluating combination regimens involving hypomethylating agents and immunotherapies. Rising adoption of precision medicine and continuous advancements in biomarker guided cancer treatment strategies are further driving demand for quizartinib tablets across specialized oncology care settings worldwide.
Market Key Insights
The Quizartinib Tablets market is projected to grow from $612.1 million in 2024 to $1.49 billion in 2034. This represents a CAGR of 9.3%, reflecting rising demand across Acute Myeloid Leukemia Treatment, Relapsed or Refractory AML Treatment, and Clinical Trials for Other Malignancies.
Novartis International AG, Acerta Pharma, Apellis Pharmaceuticals Inc are among the leading players in this market, shaping its competitive landscape.
U.S. and Germany are the top markets within the Quizartinib Tablets market and are expected to observe the growth CAGR of 6.8% to 9.8% between 2024 and 2030.
Emerging markets including Brazil, India and Singapore are expected to observe highest growth with CAGR ranging between 8.9% to 11.6%.
Transition like Transition From Conventional Chemotherapy Toward Precision Targeted Leukemia Treatment Approaches is expected to add $113 million to the Quizartinib Tablets market growth by 2030.
The Quizartinib Tablets market is set to add $877 million between 2024 and 2034, with manufacturer targeting Chemotherapy Centers & Research Institutes Application projected to gain a larger market share.
With
growing prevalence of acute myeloid leukemia, and
Technological Advancements in Drug Discovery, Quizartinib Tablets market to expand 143% between 2024 and 2034.
Opportunities in the Quizartinib Tablets
Japan represents a major growth opportunity for quizartinib tablets due to the country’s advanced precision oncology infrastructure and increasing adoption of biomarker driven leukemia treatment strategies. Oncology hospitals and hematology centers are also increasingly integrating FLT3 mutation testing into routine acute myeloid leukemia diagnosis, supporting wider use of targeted oral FLT3 inhibitors. Standard quizartinib tablets used alongside chemotherapy are expected to witness the strongest growth in newly diagnosed FLT3 positive AML treatment programs. Strategic collaborations between pharmaceutical companies, diagnostic laboratories, and cancer research institutions are further strengthening personalized leukemia care and accelerating commercial opportunities across the Japanese hematologic oncology market.
Growth Opportunities in North America and Europe
North America represents the leading regional market for quizartinib tablets due to advanced hematologic oncology infrastructure, high adoption of precision medicine, and strong integration of molecular diagnostic testing in leukemia treatment pathways. The United States dominates regional demand because of early regulatory approvals, robust reimbursement frameworks, and extensive clinical trial activity involving FLT3 targeted therapies. Major opportunities are emerging in combination treatment strategies involving quizartinib with chemotherapy and immunotherapy regimens for newly diagnosed and relapsed acute myeloid leukemia patients. Competition remains strong among pharmaceutical companies developing FLT3 inhibitors and other targeted leukemia therapies, intensifying innovation and research investments. Increasing adoption of biomarker driven oncology protocols and expanding use of companion diagnostics continue to drive demand for quizartinib tablets across specialized cancer centers and hematology clinics. Growing physician awareness regarding targeted AML treatment and strong participation in oncology research networks further strengthen long term market growth across North America.
Europe remains a significant market for quizartinib tablets supported by well established healthcare systems, expanding personalized medicine initiatives, and rising investments in hematologic cancer research. Countries including Germany, France, and the United Kingdom are leading regional adoption due to strong oncology treatment infrastructure and increasing integration of FLT3 mutation testing into routine leukemia diagnosis. Major opportunities are developing in maintenance therapy applications, combination targeted treatment regimens, and expanded clinical research involving high risk acute myeloid leukemia populations. Competition is increasing among global oncology drug manufacturers and regional pharmaceutical companies focusing on targeted AML therapies and precision oncology solutions. Favorable reimbursement policies, growing geriatric populations, and rising awareness regarding mutation specific leukemia treatment continue supporting market expansion. Collaborative research programs between academic institutions, biotechnology firms, and oncology centers are also accelerating innovation and strengthening commercial opportunities for quizartinib tablets throughout the European hematologic oncology market.
Market Dynamics and Supply Chain
01
Driver: Rising FLT3 Mutated Leukemia Incidence and Precision Oncology Adoption Accelerating Demand
The increasing prevalence of FLT3 mutated acute myeloid leukemia together with expanding adoption of precision oncology approaches is also significantly driving the quizartinib tablets market. Acute myeloid leukemia patients with FLT3 internal tandem duplication mutations often experience aggressive disease progression and higher relapse risks, increasing demand for targeted treatment options capable of improving survival outcomes. At the same time, advancements in molecular diagnostics and genomic profiling technologies are also enabling earlier identification of mutation specific patient populations suitable for FLT3 inhibitor therapies. Hospitals and oncology centers are also increasingly integrating biomarker guided treatment protocols into routine hematologic cancer management, strengthening demand for targeted oral therapies such as quizartinib tablets. In addition, growing awareness regarding personalized cancer treatment, rising investments in hematologic oncology research, and expansion of companion diagnostic testing are also further
The growing development of combination therapy strategies is also emerging as a major driver for the quizartinib tablets market. Oncology researchers and pharmaceutical companies are also increasingly evaluating quizartinib in combination with chemotherapy, hypomethylating agents, and immunotherapy based regimens to improve remission durability and reduce leukemia relapse rates. This trend is also particularly important in high risk acute myeloid leukemia treatment where combination targeted therapies are also demonstrating improved clinical outcomes compared to conventional treatment approaches alone. also advances in clinical trial design, biomarker driven patient selection, and personalized treatment protocols are also accelerating adoption of FLT3 inhibitor combination therapies. Increasing regulatory support for targeted oncology research and expanding pipeline development activities are also further strengthening long term commercial potential for quizartinib tablets in hematologic cancer treatment applications.
02
Restraint: Severe Cardiac Safety Risks and Adverse Event Monitoring Limiting Wider Adoption
One of the major restraints affecting the quizartinib tablets market is the risk of severe cardiac side effects and the need for intensive patient monitoring during treatment. Quizartinib has been associated with QT interval prolongation, arrhythmias, and other serious adverse events requiring frequent electrocardiogram monitoring and electrolyte management. These safety concerns often influence physician prescribing decisions, particularly for elderly or medically complex leukemia patients. For example, hospitals and oncology centers may prefer alternative FLT3 inhibitors with more established long term safety profiles for certain patient populations. Additionally, high rates of treatment related adverse events including neutropenia, infections, and sepsis can increase hospitalization costs and negatively affect treatment continuity, limiting broader market adoption and influencing overall prescribing behavior in hematologic oncology care.
03
Opportunity: Global Combination Immunotherapy Trials Increasing Advanced FLT3 Inhibitor Development Opportunities and Elderly Acute Myeloid Leukemia Patients Driving Oral Targeted Therapy Adoption
Expanding clinical research involving combination immunotherapy and targeted leukemia treatments is generating important opportunities for quizartinib tablets globally. Pharmaceutical companies and academic cancer centers are increasingly evaluating quizartinib alongside monoclonal antibodies, immune checkpoint inhibitors, and next generation leukemia therapies to improve remission durability and reduce relapse rates. This trend is expected to strengthen demand for advanced FLT3 inhibitor formulations in relapsed and high risk AML treatment applications. The United States and Europe remain leading regions for oncology trial activity due to strong research funding and regulatory support. Growing investments in precision oncology pipelines are further accelerating future commercialization opportunities for quizartinib based combination therapies.
The growing elderly acute myeloid leukemia patient population is creating strong opportunities for quizartinib tablets in supportive and lower intensity treatment settings. Older AML patients often face challenges tolerating aggressive chemotherapy regimens, increasing demand for oral targeted therapies with personalized treatment approaches. Quizartinib tablets combined with hypomethylating agents are gaining attention for elderly FLT3 mutated patients requiring outpatient based leukemia management. North America and Europe are expected to experience significant growth due to aging populations and expanding hematology care infrastructure. Rising physician preference for targeted maintenance therapies and improved molecular screening programs are further supporting demand within this specialized patient segment.
04
Challenge: FLT3 Inhibitor Competition and Drug Resistance Reducing Long Term Market Expansion
The quizartinib tablets market also faces growing pressure from increasing competition among FLT3 targeted therapies and the emergence of treatment resistance mechanisms in acute myeloid leukemia management. Multiple approved and pipeline FLT3 inhibitors are competing for physician preference, reimbursement coverage, and clinical adoption across major oncology markets. At the same time, leukemia patients treated with quizartinib may develop secondary FLT3 mutations associated with disease relapse and reduced therapeutic effectiveness over time. For example, resistant mutations such as FLT3 D835 and F691 variants have been identified in relapsed patients receiving quizartinib therapy, limiting long term response durability. These clinical challenges encourage healthcare providers to adopt combination therapies or alternative targeted treatments, reducing standalone market penetration and increasing competitive intensity across the precision oncology treatment landscape.
Supply Chain Landscape
1
Raw Material Procurement
Department of PharmaceuticalsActive Pharmaceutical Ingredients
2
Drug Synthesis
Daiichi SankyoDeciphera Pharmaceuticals
3
Tablet Formulation
Baxter BioPharma SolutionsRecipharm
4
Distribution & Retail
WalgreensCVS Health
1
Raw Material Procurement
Department of PharmaceuticalsActive Pharmaceutical Ingredients
2
Drug Synthesis
Daiichi SankyoDeciphera Pharmaceuticals
3
Tablet Formulation
Baxter BioPharma SolutionsRecipharm
4
Distribution & Retail
WalgreensCVS Health
Use Cases of Quizartinib Tablets in Acute Myeloid Leukemia Treatment & Relapsed or Refractory AML Treatment
Acute Myeloid Leukemia Treatment : Acute myeloid leukemia treatment represents the primary application for quizartinib tablets due to the increasing adoption of targeted therapies for FLT3 mutation positive leukemia patients. Standard oral quizartinib tablets are commonly administered in combination with induction and consolidation chemotherapy to improve remission rates and reduce disease progression risks. These tablets selectively inhibit FLT3 signaling pathways responsible for abnormal leukemia cell proliferation, offering a more precise treatment approach compared to conventional chemotherapy alone. Hematology specialists increasingly prefer targeted FLT3 inhibitor therapies because they support personalized treatment strategies and improve overall disease management. Growing use of molecular diagnostic testing and biomarker based oncology protocols continues to strengthen demand for quizartinib tablets in specialized leukemia treatment programs globally.
Relapsed or Refractory AML Treatment : Relapsed or refractory acute myeloid leukemia is a significant application area for quizartinib tablets because patients with recurrent FLT3 mutated disease often require targeted salvage therapy options. Oral quizartinib tablets are widely used in this segment due to their ability to inhibit resistant leukemia cell growth and provide therapeutic benefits for patients who do not respond adequately to standard chemotherapy regimens. These targeted therapies are frequently utilized in hematology oncology centers and advanced cancer treatment hospitals as part of combination or maintenance treatment protocols. Increasing relapse rates in high risk AML populations and growing clinical preference for mutation targeted therapies are supporting stronger adoption of quizartinib tablets within relapsed leukemia management strategies worldwide.
Clinical Trials for Other Malignancies : Clinical trials for other malignancies are emerging as an important application segment for quizartinib tablets as oncology researchers investigate broader therapeutic potential beyond acute myeloid leukemia. Selective FLT3 inhibitor quizartinib tablets are increasingly evaluated in combination with immunotherapies, hypomethylating agents, and targeted oncology drugs for treating various hematologic cancers and genetically driven malignancies. Research institutions and pharmaceutical companies are exploring the effectiveness of quizartinib in myelodysplastic syndromes and other mutation associated blood cancers requiring precision treatment approaches. Rising investments in personalized oncology research and biomarker guided clinical studies are expanding development opportunities for quizartinib based therapies. This trend is expected to support future market growth through pipeline expansion and broader oncology treatment applications.
Impact of Industry Transitions on the Quizartinib Tablets Market
As a core segment of the Pharmaceutical industry,
the Quizartinib Tablets market develops in line with broader industry shifts.
Over recent years, transitions such as Transition From Conventional Chemotherapy Toward Precision Targeted Leukemia Treatment Approaches and Transition From Monotherapy Leukemia Management Toward Combination Based Oncology Treatment Strategies have redefined priorities
across the Pharmaceutical sector,
influencing how the Quizartinib Tablets market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition From Conventional Chemotherapy Toward Precision Targeted Leukemia Treatment Approaches
The quizartinib tablets industry is transitioning from broad spectrum chemotherapy based leukemia treatment toward precision targeted oncology approaches focused on specific genetic mutations. Healthcare providers increasingly utilize FLT3 mutation testing to identify acute myeloid leukemia patients who may benefit from targeted FLT3 inhibitor therapies such as quizartinib. This transition is improving personalized treatment selection and reducing reliance on generalized chemotherapy protocols with higher toxicity profiles. For example, hematology oncology centers now routinely integrate molecular diagnostics and biomarker guided treatment planning into leukemia management programs. The shift is also influencing pharmaceutical research, diagnostic testing industries, and hospital oncology infrastructure by increasing demand for genomic profiling technologies and personalized cancer care services.
02
Transition From Monotherapy Leukemia Management Toward Combination Based Oncology Treatment Strategies
The market is rapidly transitioning from standalone FLT3 inhibitor use toward combination based treatment strategies designed to improve long term remission outcomes in acute myeloid leukemia. Oncology researchers and pharmaceutical companies increasingly combine quizartinib tablets with chemotherapy, hypomethylating agents, and immunotherapy regimens to address relapse risks and drug resistance challenges. This transition is expanding clinical trial activity and encouraging development of integrated hematologic oncology treatment protocols. For example, major cancer research institutions are evaluating combination targeted therapies for elderly and relapsed AML patient populations requiring more durable disease control. The shift is strengthening collaboration between biotechnology companies, oncology drug developers, and precision medicine research organizations across the global cancer treatment ecosystem.